Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-cash Items: 2015-2024

Historic Non-cash Items for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Dec 2024 value amounting to $6.7 million.

  • Syndax Pharmaceuticals' Non-cash Items fell 87.92% to $6.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.7 million, marking a year-over-year decrease of 87.92%. This contributed to the annual value of $6.7 million for FY2024, which is 21.65% up from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Non-cash Items of $6.7 million as of Q4 2024, which was down 87.92% from $55.1 million recorded in Q4 2023.
  • Syndax Pharmaceuticals' 5-year Non-cash Items high stood at $88.0 million for Q4 2022, and its period low was $83,000 during Q1 2022.
  • Its 3-year average for Non-cash Items is $44.2 million, with a median of $55.1 million in 2023.
  • In the last 5 years, Syndax Pharmaceuticals' Non-cash Items slumped by 99.74% in 2022 and then soared by 93,634.94% in 2023.
  • Quarterly analysis of 5 years shows Syndax Pharmaceuticals' Non-cash Items stood at $81.9 million in 2020, then declined by 16.27% to $68.6 million in 2021, then rose by 28.29% to $88.0 million in 2022, then slumped by 37.41% to $55.1 million in 2023, then crashed by 87.92% to $6.7 million in 2024.
  • Its Non-cash Items was $6.7 million in Q4 2024, compared to $55.1 million in Q4 2023 and $82.7 million in Q3 2023.